Recent clinical advancements of KRAS G12C inhibitors have generated increased interest in the fight to bring an end to RAS driven cancers. However, their specificity to only target G12C mutations, leaves huge untapped therapeutic potential to target all RAS driven cancers beyond the lungs. This calls for continued research efforts by industry and academic experts alike.
The Digital RAS- Targeted Drug Discovery Summit is the premium forum for cellular, preclinical and translational RAS experts to explore potential strategies to tackle undrugged RAS oncogenes beyond KRAS G12C.
As part of our industry leading and dedicated RAS conference series, this exciting next iteration is shining the spotlight on:
- Identifying key learnings from known pre-clinical and clinical data for viable KRAS direct inhibitors to effectively drug all RAS isoforms
- Exploring G12C pre-clinical and clinical data to optimise future RAS targeting strategies
- Learning from the patterns of RAS mutations to understand prognostic or predictive power in various cancer types beyond lung cancer
Join senior experts from leading biotech, large pharma and pioneering academic institutions at the Digital RAS- Targeted Drug Discovery Summit as they identify future models and strategies for streamlining anti-RAS therapeutics into the clinic.
Take advantage of our group discounts, academic rates and earlybird savings - don't miss out register now for the best rate!
Workshop Day Only - Industry Pricing GBP 1048.00
Conference Only - Industry Pricing GBP 1749.00
Conference + Workshop Day - Industry Pricing GBP 2646.00
Workshop Day Only - Academic Pricing GBP 897.00
Conference Only - Academic Pricing GBP 1399.00
Conference + Workshop Day - Academic Pricing GBP 1996.00
Category: Conferences | Science, Health & Medicine | Pharmaceuticals
Speakers: Alexander Stoeck, Merck, Dafna Bar-Sagi, NYU Langone School of Medicine, Darryl McConnell, Boehringer Ingelheim, Julian Downward, Francis Crick Institute, Caroline Phillips, Redx Pharma, Tina Yuan, Novartix, Steve Kelsey, Revolution Medicines, Jurgen Moll, Sanofi, Anthony Partridge, Merck Sharp & Dohme, John O’Bryan, Medical University of South Carolina, Sharon Campbell, University of North Carolina, Shubham Pant, MD Anderson Cancer Center, Charly Chahwan, SyntheX, Jeremie Mortier, Bayer, Juan Perez, Allinky Biopharma, Colin Lindsay, The Christie NHS Foundation Trust, Gopal Sapkota, University of Dundee, Aaron Hobbs, Medical University of South Carolina, Terry Rabbitts, Institute of Cancer Research London, Gary Piazza, University of South Alabama Mitchell Cancer Institute, Tommy Turbyville, Frederick National Laboratory for Cancer Research, Sara Mainardi, Netherlands Cancer Institute, Vadim Gaponeko, University of Illinois at Chicago